Neuropathic%20pain News

News

Physiotherapy improves neuropathic pain biomarker profile

20220704180000

Physiotherapeutic interventions, like exercise therapy and electro-acupuncture, appear to be effective at reducing the expression of neuropathic pain biomarkers, reveals a new systematic review.

Sustained-release noninferior to immediate-release pregabalin formulation

20220304060000

The novel once-daily sustained-release (SR) pregabalin formulation is safe and as good as the twice-daily immediate-release (IR) formulation at reducing peripheral neuropathic pain, according to the results of a phase III trial.

Mirogabalin expands treatment option for Asians with peripheral neuropathic pain

Jairia Dela Cruz, 20210603140000

Mirogabalin besylate appears to provide an early analgesic effect in Asian patients with peripheral neuropathic pain (PNP) with a tolerable safety profile, according to a pooled analysis of two phase III studies.

Immunoglobulin holds promise for treatment-resistant polyneuropathy in diabetics

Jairia Dela Cruz, 20200122090000

Treatment with intravenous immunoglobulin (IVIG) offers significant pain relief in patients with painful diabetic polyneuropathy (DPN) resistant to standard therapies, without deleterious side effects, according to the results of a trial.

High-voltage pulsed radiofrequency of dorsal root ganglion helps relieve pain

20200109060000

Delivering high-voltage pulsed radiofrequency of dorsal root ganglion via a multifunctional electrode yields significant pain relief and may prove valuable in the treatment of chronic lumbosacral radicular pain with neuropathic features, according to a recent study.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Galcanezumab: Empowering migraineurs on the journey to migraine-freedom

03 Mar 2021

Galcanezumab (Emgality^®, DKSH Singapore) was developed to target calcitonin gene-related peptide (CGRP) to prevent migraine._1-3 At the symposium to mark the launch of Emgality^® in Singapore on 23 January 2021 chaired by Dr Jonathan Ong, Dr Patricia Pozo-Rosich provided an overview of the current clinical and real-world evidence supporting the use of galcanezumab; a panel discussion led by Dr Ho King Hee and Dr Zhao Yi Jing also highlighted local headache specialists’ experience in the use of CGRP monoclonal antibodies (mAbs) in the treatment of patients with migraine.

Updates on migraine management with rimegepant

03 Sep 2023

Migraine is a debilitating neurological condition that affects millions of people worldwide, causing intense headaches, sensory disturbances, and a significant decline in quality of life. Approximately one-third of patients encounter aura, which encompasses transient focal neurological disturbances that precede the attack. [Lancet 2017;390:1211-1259; Headache 2021;61:1021-1039]